Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05533697 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 34 → 39 locationsv21
  2. Trial sites expanded: 31 → 34 locationsv20
  3. Trial sites expanded: 28 → 31 locationsv19
  4. Study sites: 27 to 28v18
  5. Study sites: 26 to 27v17
Show 15 earlier versionsHide 15 earlier versions
  1. Enrollment target: 194 to 361v16 Show 7 more changesShow less
    • Primary and study completion dates: Dec 8, 2027 to Feb 18, 2032
    • Primary endpoints: 2 to 4
    • Start date: Aug 18, 2022 to Sep 1, 2022
    • Interventions: Pembrolizumab (Biological), mRNA-4359 (Biological) to Ipilimumab (Biological), Nivolumab (Biological), Pembrolizumab (Biological), mRNA-4359 (Biological)
    • Eligibility criteria expanded, about 270 words
    • Secondary endpoints: 5 to 11
    • Study arms: 3 to 9
  2. Re-verified, no change to tracked fieldsv15
  3. Study sites: 27 to 26v14
  4. Study sites: 26 to 27v13
  5. Study sites: 24 to 26v12
  6. Study sites: 17 to 24v11
  7. Study sites: 15 to 17
    • Eligibility criteria expanded, about 37 words
    v10
  8. Study sites: 13 to 15v9
  9. Study sites: 10 to 13v8
  10. Site details revised at 1 of 10 sitesv7
  11. Study sites: 11 to 10v6
  12. Site details revised at 1 of 11 sitesv5
  13. Study sites: 10 to 11v4
  14. Site details revised at 1 of 10 sitesv3
  15. Site details revised at 2 of 10 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Trial Details
NCT Number NCT05533697
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Advanced Solid Tumors
Related terms Neoplasm Metastasis, Neoplasms, Recurrence
Enrollment 361 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov